BLOG

biospace

Pivots During Pandemic Bring Patient-Centric Options to Rare Disease Patients

X4 Pharmaceuticals is developing a class of small molecule therapeutics that work as antagonists of chemokine receptor, CXCR4, the disruption of which is implicated in a number of primary immunodeficiencies (PIs) and cancers.